From: Potential immunomodulatory effects of latent toxoplasmosis in humans
Age P | Sex P | Toxo P | sex-toxo P | women-neg mean | women-pos mean | men-neg mean | men-pos mean | |
---|---|---|---|---|---|---|---|---|
all immunology outpatients N = 440 | ||||||||
leukocytes (× 106/L) | 0.412 | 0.002* | 0.502 | 0.054 | 6913.136 | 7229.730 | 6572.973 | 5750.000 |
neutrophils (× 109/L) | 0.011* | 0.009* | 0.811 | 0.184 | 4.059 | 4.471 | 3.729 | 3.396 |
lymphocytes (× 109/L) | 0.000* | 0.047* | 0.719 | 0.152 | 2.015 | 1.985 | 1.997 | 1.644 |
monocytes (× 109/L) | 0.751 | 0.506 | 0.107 | 0.024* | 0.508 | 0.518 | 0.548 | 0.451 |
eosinophils (× 109/L) | 0.423 | 0.227 | 0.793 | 0.699 | 0.185 | 0.201 | 0.223 | 0.216 |
basophils (× 109/L) | 0.581 | 0.016* | 0.185 | 0.250 | 0.047 | 0.046 | 0.042 | 0.032 |
patients with allergies, seasonal allergic rhinitis J.30.1-4, N = 117 | ||||||||
leukocytes (× 106/L) | 0.600 | 0.191 | 0.268 | 0.351 | 689.059 | 774.375 | 667.500 | 668.000 |
neutrophils (× 109/L) | 0.511 | 0.111 | 0.326 | 0.339 | 4.058 | 4.924 | 3.733 | 3.892 |
lymphocytes (× 109/L) | 0.006* | 0.961 | 0.666 | 0.991 | 2.020 | 1.953 | 2.128 | 1.990 |
monocytes (× 109/L) | 0.701 | 0.329 | 0.502 | 0.421 | 0.475 | 0.534 | 0.555 | 0.544 |
eosinophils (× 109/L) | 0.278 | 0.641 | 0.320 | 0.496 | 0.200 | 0.269 | 0.224 | 0.218 |
basophils (× 109/L) | 0.858 | 0.120 | 0.483 | 0.630 | 0.050 | 0.049 | 0.041 | 0.032 |
patients with immunodeficiencies, D89.9, N = 250 | ||||||||
leukocytes (× 106/L) | 0.958 | 0.049* | 0.152 | 0.053 | 670.876 | 690.000 | 669.677 | 535.714 |
neutrophils (× 109/L) | 0.078 | 0.067 | 0.282 | 0.184 | 4.026 | 4.176 | 3.832 | 3.207 |
lymphocytes (× 109/L) | 0.000* | 0.129 | 0.256 | 0.051 | 1.937 | 1.977 | 2.022 | 1.440 |
monocytes (× 109/L) | 0.800 | 0.329 | 0.039* | 0.018* | 0.505 | 0.512 | 0.549 | 0.406 |
eosinophils (× 109/L) | 0.919 | 0.065 | 0.806 | 0.937 | 0.180 | 0.190 | 0.241 | 0.246 |
basophils (× 109/L) | 0.121 | 0.175 | 0.172 | 0.201 | 0.045 | 0.045 | 0.044 | 0.031 |